DNA-PK: Relaying the insulin signal to USF in lipogenesis
Open accessAbstract
To meet the constant energy requirement in the face of highly variable food supply, mammals employ intricate and precise mechanisms for energy storage. When total energy intake is in excess of energy expenditure such as after a meal, excess carbohydrates are converted to fatty acids (de novo lipogenesis). Excess fatty acids are then converted to triacylglycerol to be stored in adipose tissue and released as oxidative fuels for other tissues during times of energy need such as fasting and exercise. In sustaining the balance between energy excess and energy deficiency, the process of lipogenesis is tightly controlled by nutritional and hormonal conditions1. Thus, enzymes involved in fatty acid and fat synthesis are tightly and coordinately regulated during fasting/feeding: Activities of these enzymes are very low in fasting due to the increase in glucagon/cAMP levels. Conversely, in the fed condition, especially after a high carbohydrate meal, activities of these enzymes drastically increase as blood glucose and insulin levels rise1. Fatty acid synthase (FAS), a central lipogenic enzyme, plays a crucial role in de novo lipogenesis by catalyzing all of the seven reactions involved in fatty acid synthesis. While FAS is not known to be regulated by allosteric effectors or by covalent modification, its transcription is exquisitely regulated by fasting/feeding and by insulin1. The FAS promoter thus provides an excellent model system to dissect the transcriptional activation of lipogenesis by feeding/insulin. In early studies of insulin regulation of the FAS promoter, we found that Upstream Stimulatory Factor (USF) binding to the -65 E-box is required for transcriptional activation by insulin2,3,4. The critical role of USF in the activation of the FAS promoter by insulin was further verified by overexpressing dominant negative or wild type forms of USF2,3. The induction of FAS by fasting/feeding was significantly impaired in USF knockout mice5. Functional analysis and chromatin immunoprecipitation (ChIP) in mice transgenic for various 5′ deletions and mutations of the FAS promoter-CAT reporter gene showed that USF binding to the -65 E-box is required for feeding/insulin-mediated FAS promoter activation in vivo6. Notably, USF binding was detected in both fasted and fed states. On the FAS promoter, USF recruits another transcription factor SREBP-1, whose level increases upon insulin treatment via the PI3K pathway7, to bind the -150 SRE and mediate insulin/feeding responsiveness8. Although early studies of ectopically expressed SREBP-1 in cultured cells has been shown to bind the -65 E-box9, the functional analysis and chromatin immunoprecipitation (ChIP) in mice transgenic for various 5′ deletions and mutations of the FAS promoter-CAT reporter gene clearly showed SREBP-1 binds the -150 SRE, but not -65 E-box to activate the FAS promoter during feeding/insulin treatment in vivo6. Although SRBEP-1c binding to the -150 SRE is critical for the feeding/insulin response, SREBP-1c itself cannot bind the SRE without being recruited by USF, which is constitutively bound to the -65 E-box4, 6,10. Many lipogenic promoters contain a closely spaced E-box and SRE in the proximal promoter region, and a similar mechanism for activation of several lipogenic genes has been documented previosuly4. Possibly, the SREBP-1c promoter is also regulated by USF and SREBP-1c in response to feeding/insulin. Thus, USF, along with SREBP-1c, plays a critical role in mediating the transcriptional activation of lipogenesis in response to feeding/insulin. Studies have shown that LXR may play a role in the transcriptional regulation of lipogenesis by activating SREBP-1c transcription11. LXR has also been reported to directly regulate the FAS promoter in cultured cells12. A carbohydrate response element (ChoRE) where ChREBP can bind has also been reported to be present far upstream of the FAS promoter region13. Nevertheless, FAS promoter-reporter transgenic mice studies showed that the FAS promoter that contains both an E-box and SRE, but lacks a LXRE or ChoRE, is sufficient for high level activation of the FAS promoter during fasting/feeding suggesting that binding of LXR or ChREBP may not be critical in vivo6. Regardless, questions remain in understanding the FAS promoter activation involving USF and SREBP. Apart from HAT/HDAC, are other coactivators required for activation? What chromatin remodeling machinery and mediators are recruited to the FAS promoter? Are there common mechanisms to explain the transcriptional regulation of other coordinately regulated lipogenic genes? Is chromatin folding involved in sharing transcription machineries among lipogenic gene promoters? Further studies are necessary to understand the details of the transcriptional activation of lipogenic genes. While many metabolic effects of insulin are mediated through protein phosphorylation via the well characterized PI3K cascade which activates PKB/Akt, insulin can also
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ChREBP is activated by carbohydrate uptake.
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [83]
DNL is minimal during fasting but increases after a meal as glucose and insulin levels rise.
“DNL is minimal during fasting but increases after a meal as glucose and insulin levels rise, activating insulin signaling via PI3K, AKT, aPKC, mTORC, DNA-dependent protein kinase, and phosphatases [34,83].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [83]
Insulin activates specific kinases and phosphatases that can modify transcription factors such as USF, SREBP1c, ChREBP, and LXR, or regulate their expression.
“Thus, insulin activates specific kinases and phosphatases that can modify transcription factors such as upstream stimulatory factor (USF), SREBP1c, ChREBP, and liver X receptor (LXR), or regulate the expression of these transcription factors (Fig. 4) [34,83].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [83]
Monosaccharides activate ChREBP and other key lipogenic transcription factors-including SREBP1c, LXR, and PPARγ-via insulin-independent mechanisms.
“Supporting this perspective, monosaccharides have been shown to activate ChREBP and other key lipogenic transcription factors—including SREBP1c, LXR, and PPARγ—via insulin-independent mechanisms [34,70,83,86,99].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y. K., Lobaccaro, J. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,693 · see citing works
Kim, J. B., Sarraf, P., Wright, M., Yao, K., Mueller, E., Solanes, G., Lowell, B. B., & Spiegelman, B. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1411 · Cited by 792 · see citing works
Joseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E., Walczak, R., Collins, J. L., Osborne, T. F., & Tontonoz, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111041200 · Cited by 779 · see citing works
Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription
Ishii, S., Iizuka, K., Miller, B. C., & Uyeda, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405238101 · Cited by 416 · see citing works
A Role of DNA-PK for the Metabolic Gene Regulation in Response to Insulin
Wong, R. H.-F., Chang, I., Hudak, C. S. S., Hyun, S., Kwan, H. Y., & Sul, H. S. (2009) · Cell · doi:10.1016/j.cell.2008.12.040 · Cited by 253 · see citing works
Self-citationLatasa, M.-J., Moon, Y. S., Kim, K., & Sul, H. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180306597 · Cited by 157 · see citing works
Self-citationWang, D., & Sul, H. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26367 · Cited by 154 · see citing works
Self-citationIsolation and Characterization of PNUTS, a Putative Protein Phosphatase 1 Nuclear Targeting Subunit
Allen, P. B., Kwon, Y., Nairn, A. C., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.4089 · Cited by 151 · see citing works
Wang, D., & Sul, H. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25420 · Cited by 143 · see citing works
Self-citationCasado, M., Vallet, V. S., Kahn, A., & Vaulont, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2009 · Cited by 137 · see citing works
Wang, D., & Sul, H. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28716 · Cited by 118 · see citing works
Self-citationLatasa, M.-J., Griffin, M. J., Moon, Y. S., Kang, C., & Sul, H. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5896-5907.2003 · Cited by 109 · see citing works
Self-citationThe Role of Protein Phosphatase-1 in Insulin Action
Brady, M. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.157 · Cited by 106 · see citing works
Griffin, M. J., Wong, R. H.-F., Pandya, N., & Sul, H. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610566200 · Cited by 69 · see citing works
Self-citationFatty acid synthesis in eukaryotes
Sul, H. S., & Smith, S. (2008) · Elsevier eBooks · doi:10.1016/b978-044453219-0.50008-8 · Cited by 35 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Transcriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646 · see citing works
Self-citationTruong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84 · see citing works
“In particular, two major transcription factors have been studied much [2,10,84]: SREBP1c, which is controlled by both insulin signaling and insulin-independent pathways [2,20,75], and ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
Influential
- Authors
- Wong, R. H. F., & Sul, H. S.
- Affiliations
- University of California, Berkeley (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Sul, Hei Sook
- ORCID
- Sul, Hei Sook
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2009-07
- Volume
- 8
- Issue
- 13
- Pages
- 1973-1978
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC2862631
- OpenAlex
- W2057764248
- Cited by
- 20
- References
- 15
- Citations by year
- 2025: 2 · 2023: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- U.S. Forest Service
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081098)
- National Institute of Neurological Disorders and Stroke (R01NS050266, R01NS039996)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- DNA-dependent protein kinase, insulin signaling, USF, fatty acid synthase, de novo lipogenesis, SREBP1, PI3K signaling, E-box, SRE, transcriptional regulation, energy homeostasis, adipose tissue, chromatin remodeling, histone acetylation, histone deacetylase, histone methyltransferase
- MeSH terms
- Humans, Insulin, Signal Transduction, Lipogenesis, Upstream Stimulatory Factors, DNA-Activated Protein Kinase, Fatty Acid Synthases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review